

Sarah Gooding

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3137411/publications.pdf>

Version: 2024-02-01

17
papers

302
citations

1163117

8
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

574
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. <i>Blood</i> , 2021, 137, 232-237.	1.4	90
2	Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease. <i>Nature Communications</i> , 2019, 10, 4533.	12.8	46
3	Hepcidin is regulated by promoter-associated histone acetylation and HDAC3. <i>Nature Communications</i> , 2017, 8, 403.	12.8	45
4	New approaches to targeting the bone marrow microenvironment in multiple myeloma. <i>Current Opinion in Pharmacology</i> , 2016, 28, 43-49.	3.5	25
5	Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice. <i>Journal of Infection</i> , 2007, 54, e169-e174.	3.3	22
6	Key stages of bone marrow B-cell maturation are defective in patients with common variable immunodeficiency disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 487-490.e2.	2.9	20
7	Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response. <i>British Journal of Haematology</i> , 2022, 197, 293-301.	2.5	16
8	Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs. <i>PLoS ONE</i> , 2015, 10, e0136207.	2.5	10
9	Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2854-2864.	7.0	6
10	Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways. <i>Frontiers in Genetics</i> , 2022, 13, 831779.	2.3	5
11	Gremlin 1 – small protein, big impact: the multiorgan consequences of disrupted BMP antagonism. <i>Journal of Pathology</i> , 2020, 251, 349-352.	4.5	4
12	Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Ibrandomide-Treated Myeloma Patients. <i>Blood</i> , 2021, 138, 730-730.	1.4	4
13	Validation of clinical-grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly-diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes Project. <i>EJHaem</i> , 2021, 2, 809.	1.0	3
14	Precision medicine for liver tumours with quantitative MRI and whole genome sequencing (Precision1) Tj ETQq0 0 Q rgBT /Overlock 10 T	1.9	3
15	Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients. <i>Blood</i> , 2021, 138, 458-458.	1.4	1
16	A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma. <i>Blood</i> , 2021, 138, 2676-2676.	1.4	1
17	Anti-BCMA Immunotherapy in Myeloma: Is It the Tumor or the Immune System That Most Undermines Outcomes?. , 2022, 19, .		0